Lily Zou, Degron Therapeutics CEO
Takeda enters hot molecular glue space in up to $1.2B pact with Degron
Takeda is adding the popular “molecular glue” approach to its R&D capabilities in an up to $1.2 billion collaboration with a young biotech.
The Japanese …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.